Products

  1. Home
  2. Products
  3. Bone & Mineral Metabolism
  4. IDKmonitor® Adalimumab Drug Level ELISA

IDKmonitor® Adalimumab Drug Level ELISA

$946.00

Available with Lead Time!

Method: ELISA
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 10 µl
Species: Human
Incubation time: 2h 10m
Standard Range: 4.15-225 ng/ml
Size: 96 wells
Regulatory Status: For research use only in the U.S.
Kit Manual: Download

The IDKmonitor® Adalimumab Drug Level ELISA is intended for the quantitative determination of free adalimumab (therapeutic antibody against TNFα, e.g. HUMIRA®) in EDTA plasma and serum.

For research use only. Not for use in diagnostic procedures.

For Laboratory Professional Use Only.

This is the RUO version of Immundiagnostik part number K 9657.

Test Principle of the IDKmonitor® Adalimumab Drug Level ELISA

The IDKmonitor® Adalimumab Drug Level ELISA is designed to quantitate free adalimumab (therapeutic antibody against TNFα, e. g. HUMIRA®) in EDTA plasma or serum samples.

In the first incubation step, the free adalimumab from the sample is bound to the specific monoclonal anti-adalimumab antibody coated on the plate. To remove all unbound substances, a washing step is carried out. In a further incubation step, a Peroxidase-labeled antibody is added. Tetramethylbenzidine (TMB) is used as a substrate for peroxidase. Finally, an acidic stop solution is added to terminate the reaction.

The color changes from blue to yellow. The intensity of the yellow color is directly proportional to the concentration of free adalimumab in the sample. A dose-response curve of the absorbance unit (optical density, OD) vs. concentration is generated, using the values obtained from the standard. The concentrations of free adalimumab in the samples are determined directly from this curve.

 

Additional information

Weight 35.5 oz
Dimensions 6.5 × 10 × 4.5 in
Social media & sharing icons powered by UltimatelySocial

Become an IDK Insider!

Join our mailing list to receive the latest news and updates from Immundiagnostik, Inc.

 
 
 
 

You have Successfully Subscribed!